Related Experiment Video

Updated: Sep 28, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Perspectives on anti-HER monoclonal antibodies

Malcolm Ranson1, Mark X Sliwkowski

  • 1Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. malcolm.ransom@man.ac.uk

Oncology
|November 8, 2002
PubMed

Insights

Monoclonal antibodies (MAbs) show promise for cancer therapy, particularly targeting HER1 and HER2 receptors. Research explores enhancing MAb efficacy through drug conjugation and inhibiting receptor dimerization for improved solid tumor treatment.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Humanized or chimeric monoclonal antibodies (MAbs) have demonstrated success in cancer therapy, exemplified by Herceptin for HER2-overexpressing breast cancer.
  • The human epidermal growth factor receptor (HER/ErbB) family, specifically HER1 and HER2, represents a critical target for MAb-based cancer therapeutics.
  • Existing therapies like cetuximab (Erbitux) target HER1, while strategies to enhance HER2-targeted treatments are under investigation.

Purpose of the Study:

  • To review alternative approaches for MAb-based anti-HER therapy.
  • To explore methods for augmenting the efficacy of HER2-targeted MAbs.
  • To discuss strategies aimed at improving treatment outcomes for solid tumors.

Main Methods:

  • Review of current research on monoclonal antibodies (MAbs) targeting HER1 and HER2.
  • Investigation of strategies to enhance MAb efficacy, including drug conjugation and inhibition of receptor dimerization.
  • Analysis of HER2's role as a dimerization partner in HER-ligand-dependent tumor growth.

Main Results:

  • Monoclonal antibodies (MAbs) targeting HER1, such as cetuximab, are in advanced clinical development.
  • Strategies to enhance trastuzumab (Herceptin) efficacy include coupling it with chemotherapeutic agents for targeted cytotoxic delivery.
  • Inhibiting the association of HER2 with other HER family members via MAbs shows potential for effective anti-cancer therapy.

Conclusions:

  • MAb-based therapies targeting HER1 and HER2 offer significant potential for treating various solid tumors.
  • Novel approaches, including drug conjugation and disruption of receptor dimerization, are being explored to maximize MAb effectiveness.
  • These advanced MAb strategies hold promise for improving patient outcomes in cancer treatment.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Cross-reactivity00:42

Cross-reactivity

Overview
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.